New injectable drug offers up to 93.9% reduction in heart cholesterol

Eli Lilly’s Lepodisiran shows unprecedented reduction in hereditary heart disease risk, sparking Phase 3 trials to validate long-term clinical benefits and redefine treatment for high Lp(a) patients; patients in Israel are participating in…